

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: **Jeremy I. Levin, et al.**

Serial No.:

Group No.:

Confirmation No:

Customer No. **25291**

Filed:

Examiner:

For:

**ALKYNYL CONTAINING HYDROXAMIC ACID COMPOUNDS  
AS MATRIX METALLOPROTEINASE/TACE INHIBITORS**

Commissioner for Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Preliminary to the examination of the present application please amend the application as follows.

IN THE SPECIFICATION

Please replace the paragraph beginning on page 1, line 4, with the following:

--This is a divisional of copending application serial no. 09/492,686 filed on January 27, 2000, which application claims the benefit of U.S. Provisional Application No. 60/155,184 filed January 27, 1999, the entire disclosure of each being hereby incorporated by reference.--

~~~~~  
CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL909159916US addressed to the Commissioner for Patents, Washington, DC 20231.


12-21-01

Date

Regina Benson  
Regina Benson

# In the Claims

1. A compound of formula



I

wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;

R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;


A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y;  
and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the  
carbon atom to which they are attached may not form a piperdinyll or  
tetrahydropyranyll ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.

4. A method of inhibiting pathological changes mediated by TNF- $\alpha$  converting enzyme  
(TACE) in a mammal in need thereof which comprises administering to said mammal a  
therapeutically effective amount of a compound having the formula



I

wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms,  
alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-  
cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;

R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of  
2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -  
C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-  
NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6  
carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18  
carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub>  
and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to  
which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-  
cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;


A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y;  
and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the carbon atom to which they are attached may not form a piperdinyll or tetrahydropyranyll ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound having the formula



I

wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;

R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;

A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the carbon atom to which they are attached may not form a piperdinyll or tetrahydropyranyll ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.


Please cancel claim 3, without prejudice.

#### REMARKS

The present application is a divisional of 09/492,686. The specification has been amended to reflect the complete prosecution history. The claims have been amended to delete subject matter which has been allowed in the parent application.

Attached hereto is a marked-up version of the changes made to the application by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Applicants believe that the present application is in condition for allowance and respectfully request that the Examiner enter the amendment and allow the application. Favorable treatment of the application is earnestly solicited.

  
John W. Hogan, Jr.

Reg. No. 32,703

American Home Products Corporation  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (973) 683-2152

**Version with Markings to Show Changes Made**

**In the Specification**


Please replace the paragraph beginning on page 1, line 4, with the following:

This is a divisional of copending application serial no. 09/492,686 filed on January 27, 2000, which application claims the benefit of U.S. Provisional Application No. 60/155,184 filed January 27, 1999, the entire disclosure of each being hereby incorporated by reference.

~~This application claims the benefit of U.S. Provisional Application No. 60/155,184, filed January 27, 1999.~~

**In the Claims**

1. A compound of formula



wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;

R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to

which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;


A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y;  
and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the carbon atom to which they are attached may not form a piperdinyll or tetrahydropyranyll ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.

4. A method of inhibiting pathological changes mediated by TNF- $\alpha$  converting enzyme (TACE) in a mammal in need thereof which comprises administering to said mammal a therapeutically effective amount of a compound having the formula



wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;



R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;


A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the carbon atom to which they are attached may not form a piperdinyl or tetrahydropyranyl ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising a compound having the formula



I

wherein:

R<sub>1</sub> is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl;

R<sub>2</sub> and R<sub>3</sub> are each, independently, hydrogen, alkyl of 1-6 carbon atoms, -CN, or -CCH<sub>3</sub>;

R<sub>7</sub> is hydrogen, aryl, aralkyl, heteroaryl, heteroaralkyl, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 1-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, -C(O)-R<sub>1</sub>, -SO<sub>2</sub>-R<sub>1</sub>, -C(O)-NHR<sub>1</sub>, -C(O)NR<sub>5</sub>R<sub>6</sub>, -C(O)R<sub>1</sub>NR<sub>5</sub>R<sub>6</sub>, -C(O)-OR<sub>1</sub>, -C(NH)-NH<sub>2</sub>.

R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub> are each, independently, hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R<sub>8</sub> and R<sub>9</sub>, R<sub>9</sub> and R<sub>10</sub> or R<sub>10</sub> and R<sub>11</sub>, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl ring;

R<sub>12</sub> is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C<sub>4</sub>-C<sub>8</sub>-cycloheteroalkyl, or alkyl of 1-6 carbon atoms;

A is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

X is O, S, SO, SO<sub>2</sub>, NR<sub>7</sub>, or CH<sub>2</sub>;

Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and with the further proviso that if Y is phenyl, then R<sub>8</sub> and R<sub>9</sub> together with the carbon atom to which they are attached may not form a piperdinyll or tetrahydropyranyll ring; and

n is 0-2; or a pharmaceutically acceptable salt thereof.